Context Therapeutics Inc.
$2.26
▲
2.64%
2026-04-21 06:08:01
www.contexttherapeutics.com
NCM: CNTX
Explore Context Therapeutics Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$223.27 M
Current Price
$2.26
52W High / Low
$3.62 / $0.49
Stock P/E
—
Book Value
$0.66
Dividend Yield
—
ROCE
-65.65%
ROE
-46.39%
Face Value
—
EPS
$-0.38
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
15
Beta
1.83
Debt / Equity
0.18
Current Ratio
8.52
Quick Ratio
8.52
Forward P/E
-5.38
Price / Sales
—
Enterprise Value
$162.9 M
EV / EBITDA
-4.11
EV / Revenue
—
Rating
Strong Buy
Target Price
$6
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Ligand Pharmaceuticals Incorporated | $231.78 | 36.85 | $4.59 B | — | 3.1% | 13.47% | $238.31 / $98.89 | $51.44 |
| 2. | Outlook Therapeutics, Inc. | $0.37 | — | $38.71 M | — | 246.27% | 118.61% | $3.39 / $0.16 | $-0.6 |
| 3. | AtaiBeckley Inc. | $4.9 | — | $1.47 B | — | -76% | -3.9% | $6.75 / $1.29 | $0.61 |
| 4. | EyePoint, Inc. | $15.07 | — | $1.26 B | — | -74.45% | -72.19% | $19.11 / $5.3 | $3.7 |
| 5. | Enveric Biosciences, Inc. | $3.65 | — | $3.44 M | — | -210.04% | -3.04% | $17.84 / $1.71 | $3.94 |
| 6. | Boundless Bio, Inc. | $1.6 | — | $35.4 M | — | -43.97% | -46.69% | $1.78 / $0.96 | $4.4 |
| 7. | Nuvectis Pharma, Inc. | $8.33 | — | $235.78 M | — | -149.75% | -1.88% | $11.52 / $5.55 | $0.72 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -13.8 M | -10.61 M | -9.76 M | -5.53 M | -4.31 M | — |
| Net Profit | -13.03 M | -9.69 M | -8.83 M | -4.58 M | -3.34 M | — |
| EPS in Rs | -0.14 | -0.11 | -0.1 | -0.05 | -0.04 | -0.22 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -39.7 M | -29.92 M | -25.07 M | -14.88 M |
| Net Profit | -36.12 M | -26.73 M | -23.96 M | -14.84 M |
| EPS in Rs | -0.39 | -0.29 | -0.26 | -0.16 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 68.49 M | 98.13 M | 16.06 M | 37.97 M |
| Total Liabilities | 8.02 M | 2.86 M | 4.19 M | 3.21 M |
| Equity | 60.47 M | 95.27 M | 11.87 M | 34.76 M |
| Current Assets | 68.35 M | 97.9 M | 16.05 M | 37.85 M |
| Current Liabilities | 8.02 M | 2.75 M | 4.19 M | 3.21 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -26.39 M | -14.56 M | -21.05 M | -13.55 M |
| Investing CF | -2.03 M | -14.76 M | 0 M | -0.54 M |
| Financing CF | -0.02 M | 109.29 M | 0 M | -0.1 M |
| Free CF | -28.42 M | -29.31 M | -21.05 M | -14.09 M |
| Capex | -2.03 M | -14.76 M | — | -0.54 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -11.52% | -61.53% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.